<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978234</url>
  </required_header>
  <id_info>
    <org_study_id>UFAI-PF-01</org_study_id>
    <nct_id>NCT03978234</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Effect of abobotulinumtoxinA in the Gastrocnemius Muscle to Improve Equinus and Plantar Fasciitis Pain</brief_title>
  <official_title>A Phase II Clinical Trial Evaluating the Safety and Effect of abobotulinumtoxinA Injection in the Gastrocnemius Muscle to Improve Equinus and Associated Plantar Fasciitis Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Foot and Ankle Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Foot and Ankle Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to collect safety and efficacy data on injection of
      botulinumtoxinA (AbobotulinumtoxinA /Dysort) into the gastrocnemius (calf) muscle to improve
      equinus (lack of flexibility to bring the top of the foot towards the front of the leg) in
      subjects with plantar fasciitis and relieve pain associated with this condition. The use of
      AbobotulinumtoxinA is considered experimental in this study because it has not been approved
      by the United States Food and Drug Administration (FDA) for the treatment of plantar
      fasciitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 28, 2019</start_date>
  <completion_date type="Anticipated">May 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>injection</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reduction of pain (VAS scale) associated with plantar fasciitis at 8 weeks post injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>26 weeks</time_frame>
    <description>Number of product related AEs per patient that are definitely, probably, or possibly related to the product post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pain intensity instrument</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in PROMIS Pain Intensity Instrument,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pain interference instrument</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in PROMIS Pain Interference Instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Physical function Instrument</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in PROMIS Physical function instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AOFAS Ankle-Hindfoot Score</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAAM Foot and Ankle Ability Measure</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in the Foot and Ankle Ability Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrocnemius measurement</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in gastrocnemius muscle size using ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrocnemius measurement and mobility</measure>
    <time_frame>26 weeks</time_frame>
    <description>Changes in gastrocnemius range of motion/dorsiflexion using goniometer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Plantar Fascitis</condition>
  <arm_group>
    <arm_group_label>Single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbobotulinumtoxinA 300 UNT</intervention_name>
    <description>AbobotulinumtoxinA 300 UNT</description>
    <arm_group_label>Single group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years old and not older than 75 years.

          2. History of Plantar fasciitis for a minimum of 6 weeks

          3. History and physical examination consistent with plantar fasciitis and a diagnostic
             ultrasound study showing thickening of the plantar fascia &gt;5 mm (normal is 3 mm)

          4. Minimum Visual Analog Scale (VAS) score of 4.

          5. Failed conservative care with at least two of the following treatments: Stretching,
             rest, shoe modifications, insoles or orthotics, physical therapy, or cortisone
             injection.

          6. Females of childbearing potential must be willing to use acceptable methods of
             contraception (birth control pills, barriers or abstinence) during the course of the
             study and undergo pregnancy tests.

          7. Subject understands and is willing to participate in the clinical study and can comply
             with visit and post -injection questionnaire schedules.

        Exclusion Criteria:

          1. Patients with history of diabetes, back issues, nerve issues or previous surgery of
             the foot or calf.

          2. Patients with no pain in the heel region.

          3. Subject is pregnant or breast- feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://footankleinstitute.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Foot and Ankle Foundation</investigator_affiliation>
    <investigator_full_name>John T. Cano</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

